<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03410446</url>
  </required_header>
  <id_info>
    <org_study_id>INKeD-PC</org_study_id>
    <secondary_id>16-5754</secondary_id>
    <nct_id>NCT03410446</nct_id>
  </id_info>
  <brief_title>Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care</brief_title>
  <official_title>A Phase II, Open-label Clinical Trial of Intranasal Ketamine for Depression in Patients With Cancer Receiving Palliative Care (INKeD-PC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 study of the drug ketamine for the treatment of depression in cancer&#xD;
      patients receiving palliative care. The purpose of this study is to see how useful the drug&#xD;
      is at decreasing the severity of depression these patients. Ketamine will be given through&#xD;
      the nose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Greater than 25% of participants achieving a clinical response</measure>
    <time_frame>Day 8</time_frame>
    <description>Montgomery-Åsberg Depression Rating Scale (MADRS) score decreasing by &gt;50%</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Depression</condition>
  <condition>Cancer</condition>
  <condition>Palliative Care</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of ketamine will be given intranasal:&#xD;
Dose 1 will be 50 mg on Day 1&#xD;
Dose 2 will be between 50-100 mg on Day 4&#xD;
Dose 3 will be between 50-150 mg on Day 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine Hydrochloride</intervention_name>
    <description>Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written, voluntary informed consent prior to study enrollment. Participants&#xD;
             must be capable of consenting to treatment as substitute decision makers will not be&#xD;
             allowed to consent to the study on their behalf&#xD;
&#xD;
          -  Males and females ≥ 18 years of age&#xD;
&#xD;
          -  Patient is receiving palliative care at Princess Margaret Cancer Centre (PM) including&#xD;
             all in-patient units and outpatients&#xD;
&#xD;
          -  Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)&#xD;
             criteria for Major Depressive Disorder (MDD), with a current Major Depressive Episode&#xD;
             (MDE)&#xD;
&#xD;
          -  Depression severity must be in the moderate to severe range, as determined by a&#xD;
             Montgomery-Åsberg Depression Rating Scale (MADRS) score greater than or equal to 20&#xD;
&#xD;
          -  Participants must have a confirmed diagnosis of cancer and an estimated life&#xD;
             expectancy of less than twelve months, as determined by the palliative care physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of delirium or suspected delirium&#xD;
&#xD;
          -  Severe hypertension or severe cardiac decompensation&#xD;
&#xD;
          -  Previous stroke history&#xD;
&#xD;
          -  History of intolerability, hypersensitivity or allergy to ketamine&#xD;
&#xD;
          -  Patients with bipolar disorder, psychotic disorders, substance use disorders or active&#xD;
             suicidality based on a Mini-International Neuropsychiatric Interview (MINI) conducted&#xD;
             by a delegated physician will also be excluded&#xD;
&#xD;
          -  Current symptoms of psychosis or perceptual disturbances of any kind per investigator&#xD;
             discretion&#xD;
&#xD;
          -  Pregnancy or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madeline Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 28, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2018</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

